Abstract
The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is not entirely understood. Recently, the role of microRNA in this liver disease entity and its implication in disease pathogenesis and therapeutic potential has advanced rapidly over the year. While the regulation of miRNA function and its mechanism of actions on translational control of target mRNA expression remain unknown, advances in miRNA research allow identification and biochemical characterization of events that limit protein expression, which is crucial in various forms of human diseases and their subsequent development. It is hoped that further understanding of the role of microRNA in NAFLD will advance potential therapeutics and preventive measures to modify and alter this disease process.
Keywords: microRNA, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome
Current Pharmaceutical Design
Title: Role of microRNAs in Non-Alcoholic Steatohepatitis
Volume: 16 Issue: 17
Author(s): Onpan Cheung and Arun J. Sanyal
Affiliation:
Keywords: microRNA, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome
Abstract: The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is not entirely understood. Recently, the role of microRNA in this liver disease entity and its implication in disease pathogenesis and therapeutic potential has advanced rapidly over the year. While the regulation of miRNA function and its mechanism of actions on translational control of target mRNA expression remain unknown, advances in miRNA research allow identification and biochemical characterization of events that limit protein expression, which is crucial in various forms of human diseases and their subsequent development. It is hoped that further understanding of the role of microRNA in NAFLD will advance potential therapeutics and preventive measures to modify and alter this disease process.
Export Options
About this article
Cite this article as:
Cheung Onpan and J. Sanyal Arun, Role of microRNAs in Non-Alcoholic Steatohepatitis, Current Pharmaceutical Design 2010; 16 (17) . https://dx.doi.org/10.2174/138161210791208866
DOI https://dx.doi.org/10.2174/138161210791208866 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews Hypertension, Prehypertension and Blood Pressure Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy Systemic and Biophase Bioavailability and Pharmacokinetics of Nanoparticulate Drug Delivery Systems
Current Drug Delivery Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Genetic Variants of Drug Metabolizing Enzymes and Drug Transporter (ABCB1) as Possible Biomarkers for Adverse Drug Reactions in an HIV/AIDS Cohort in Zimbabwe
Current HIV Research Early Brain Injury or Vasospasm? An Overview of Common Mechanisms
Current Drug Targets Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology Non-Respiratory Manifestations of COVID-19 and Pathophysiological Evidences
New Emirates Medical Journal Novel Epigenetic Targets in Lymphoproliferative Disorders
Current Cancer Drug Targets Neurologic Sequelae in Critical Illness: Evaluation and Outcomes
Current Respiratory Medicine Reviews Desmopressin 30 Years in Clinical Use: A Safety Review
Current Drug Safety The Potential Role of Thiamine (Vitamin B1) in Diabetic Complications
Current Diabetes Reviews Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Novel Anticoagulants vs Warfarin for Stroke Prevention in Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets